Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,600 full-time employees. The company went IPO on 2000-06-28. The firm's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. The company also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
Mr. Jacob Thaysen es el Chief Executive Officer de Illumina Inc, se unió a la empresa desde 2023.
¿Qué tal es el rendimiento del precio de la acción ILMN?
El precio actual de ILMN es de $190.39, ha aumentado un 0.09% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Illumina Inc?
Illumina Inc pertenece a la industria Life Sciences Tools & Services y el sector es Health Care
¿Cuál es la capitalización bursátil de Illumina Inc?
La capitalización bursátil actual de Illumina Inc es $28.8B
¿Es Illumina Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 23 analistas han realizado calificaciones de análisis para Illumina Inc, incluyendo 8 fuerte compra, 6 compra, 13 mantener, 2 venta, y 8 fuerte venta